EVEREST Trial 2-Year Results Show Stability of Percutaneous MV Repair between Years 1 and 2

Summary

The 2-year results from the Endovascular Valve Edge-to-Edge Repair trial [EVEREST II; NCT00209274] showed that percutaneous mitral valve repair is safe and durable with measurable clinical benefits and is a therapeutic option for select patients with significant mitral regurgitation [Feldman T et al. N Engl J Med 2011].

  • Valvular Disease
  • Interventional Techniques & Devices Clinical Trials
View Full Text